Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643146 | 0.93 | KDM4E (0.44) | KDM4ESCN9AKCNH2SCN5AROCK1 | |
| SCHEMBL3150166 | 0.92 | KCNH2 (0.42) | KDM4ESCN9AKCNH2SCN5AROCK1 | |
| Hydrochloric Acid SCHEMBL3243638 | 0.92 | KDM4E (0.43) | KDM4ESCN9AKCNH2SCN5AROCK1 | |
| SCHEMBL3242638 | 0.91 | AGPAT2 (0.52) | KDM4ESCN9AKCNH2ROCK1AGPAT2 | |
| SCHEMBL3137696 | 0.91 | KDM4E (0.56) | KDM4ESCN9AKCNH2ROCK1AGPAT2 | |
| SCHEMBL3242145 | 0.91 | KCNH2 (0.49) | KDM4ESCN9AKCNH2SCN5AROCK1 | |
| SCHEMBL1643260 | 0.91 | KDM4E (0.42) | KDM4ESCN9AKCNH2SCN5AROCK1 | |
| SCHEMBL3237520 | 0.91 | KDM4E (0.45) | KDM4ESCN9AKCNH2SCN5AROCK1 | |
| SCHEMBL1642822 | 0.91 | AGPAT2 (0.54) | KDM4ESCN9AKCNH2ROCK1AGPAT2 | |
| SCHEMBL3140734 | 0.89 | ROCK2 (0.43) | KDM4ESCN9AKCNH2SCN5AROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090258888-A1 | Pyrimidine Derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-15 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | KDM4E 2029/4885SCN9A 4682/4885KCNH2 3838/4885 |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | CCNA2, MALT1, TPD52L2 | KDM4E 1063/4885SCN9A 4176/4885KCNH2 1502/4885 |
| US-20050277640-A1 | Pyrimidine derivatives for treatment of hyperproliferative disorders | TYMP, DPYD, CCNA2 | KDM4E 2029/4885SCN9A 4682/4885KCNH2 3838/4885 |
| US-20090258888-A1 | Pyrimidine Derivatives | DPYD, TYMS, TYMP | KDM4E 1993/4885SCN9A 4619/4885KCNH2 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.